Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $127.6 million.

  • Cytek Biosciences' Shares Outstanding (Diluted Average) fell 390.2% to $127.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.6 million, marking a year-over-year decrease of 390.2%. This contributed to the annual value of $130.6 million for FY2024, which is 345.33% down from last year.
  • Latest data reveals that Cytek Biosciences reported Shares Outstanding (Diluted Average) of $127.6 million as of Q3 2025, which was down 390.2% from $127.6 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Shares Outstanding (Diluted Average) high stood at $138.7 million for Q3 2022, and its period low was $36.2 million during Q2 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $123.1 million, with a median of $131.4 million in 2024.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 6992.58% in 2022, then crashed by 390.2% in 2025.
  • Over the past 5 years, Cytek Biosciences' Shares Outstanding (Diluted Average) (Quarter) stood at $81.5 million in 2021, then surged by 69.93% to $138.6 million in 2022, then dropped by 2.37% to $135.3 million in 2023, then decreased by 3.45% to $130.6 million in 2024, then fell by 2.3% to $127.6 million in 2025.
  • Its last three reported values are $127.6 million in Q3 2025, $127.6 million for Q2 2025, and $128.3 million during Q1 2025.